345 related articles for article (PubMed ID: 32351024)
21. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
[TBL] [Abstract][Full Text] [Related]
22. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
23. The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.
Varghese C; Immanuel T; Ruskova A; Theakston E; Kalev-Zylinska ML
Curr Oncol; 2021 Apr; 28(2):1544-1557. PubMed ID: 33919650
[TBL] [Abstract][Full Text] [Related]
24. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
25. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
Hultcrantz M; Ravn Landtblom A; Andréasson B; Samuelsson J; Dickman PW; Kristinsson SY; Björkholm M; Andersson TM
J Intern Med; 2020 Apr; 287(4):448-454. PubMed ID: 31927786
[TBL] [Abstract][Full Text] [Related]
26. Leukocytosis and MPNs: Where do we stand?
Coltoff A
Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
[TBL] [Abstract][Full Text] [Related]
27. Top advances of the year: Myeloproliferative neoplasms.
Bhave RR; Mesa R; Grunwald MR
Cancer; 2023 Dec; 129(23):3685-3691. PubMed ID: 37768996
[TBL] [Abstract][Full Text] [Related]
28. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
29. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
30. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
31. Bomedemstat as an investigative treatment for myeloproliferative neoplasms.
Rienhoff HY; Gill H
Expert Opin Investig Drugs; 2023; 32(10):879-886. PubMed ID: 37804041
[TBL] [Abstract][Full Text] [Related]
32. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
Harrison CN; Koschmieder S; Foltz L; Guglielmelli P; Flindt T; Koehler M; Mathias J; Komatsu N; Boothroyd RN; Spierer A; Perez Ronco J; Taylor-Stokes G; Waller J; Mesa RA
Ann Hematol; 2017 Oct; 96(10):1653-1665. PubMed ID: 28780729
[TBL] [Abstract][Full Text] [Related]
33. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
Roaldsnes C; Holst R; Frederiksen H; Ghanima W
Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
[TBL] [Abstract][Full Text] [Related]
34. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N
Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148
[TBL] [Abstract][Full Text] [Related]
35. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
37. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
[TBL] [Abstract][Full Text] [Related]
38. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
Radia D; Geyer HL
Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of myeloproliferative neoplasms in the United States.
Mehta J; Wang H; Iqbal SU; Mesa R
Leuk Lymphoma; 2014 Mar; 55(3):595-600. PubMed ID: 23768070
[TBL] [Abstract][Full Text] [Related]
40. Predictive Value of Kozak Gene Polymorphism for Thrombosis in Patients with Philadelphia-Negative MPNs.
El-Ghonemy MS; El-Ashwah S; Denewer M; Soliman EA; El-Baiomy M; Elkerdawy H; El-Sebaie A
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1195-1201. PubMed ID: 33906312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]